Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9 million, driven by a significant increase in R&D expenses to $70.9 million as it advances its obesity pipeline. The company highlighted positive clinical progress, including Phase 3 data for oral KAI-7535 in type 2 diabetes which met its primary endpoint, and Phase 1 data for injectable tri-agonist KAI-4729 showing up to 16% weight loss.
Key figures
- Eps
- 0
- Revenue
- 0
- Guidance
- Cash on hand expected to fund operations into mid-2028
- Ipo price
- 16
- Ipo shares
- 44921875
- Ipo proceeds
- 718800000
- G and a expense
- 13787000
- R and d expense
- 70873000
- Cash and equivalents
- 581900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.